Unambiguous Results
Optivia Delivers FDA Ready Reports
To order our services please call:
650-324-3177, extension 16
Toll Free: 888-OPTIVIA (888-678-4842)
Fax: 650-324-1855.
QUESTIONS?
Speak with one of our transporter specialists about your specific requirements to understand how we could help you and what kind of results yu can expect.
CONTACT OUR LAB:
888-OPTIVIA (888-678-4842)
Inhibition Studies
Optivia inhibition studies assess whether your compound inhibits the expressed transporter. Inhibitors can cause drug-drug interactions that make other substrate drugs unsafe.
The transport of a reference substrate is monitored in the presence and absence of your compound. A reduction in the transport of the marker substrate when your compound is present indicates that it inhibits the transporter. Inhibition can be caused by both substrates and non-substrates of the transporter.
Standard inhibition screening studies are performed at a single concentration of the test compound.
Full dose response curves are available to calculate the inhibition constant (IC50) of your compound.
OptiDDI-Essential&trade and OptiDDI-IC50&trade are recommended for development compounds since they were designed in accordance with the ITC Transporter White Paper and FDA Advisory Committee recommendations.
Optivia inhibition studies assess whether your compound inhibits the expressed transporter. Inhibitors can cause drug-drug interactions that make other substrate drugs unsafe.
The transport of a reference substrate is monitored in the presence and absence of your compound. A reduction in the transport of the marker substrate when your compound is present indicates that it inhibits the transporter. Inhibition can be caused by both substrates and non-substrates of the transporter.
Standard inhibition screening studies are performed at a single concentration of the test compound.
Full dose response curves are available to calculate the inhibition constant (IC50) of your compound.
OptiDDI-Essential&trade and OptiDDI-IC50&trade are recommended for development compounds since they were designed in accordance with the ITC Transporter White Paper and FDA Advisory Committee recommendations.